Pharmaceutical compound
 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | CD20 |
| Clinical data | |
| Trade names | Zevalin |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| (what is this?) (verify) | |
Ibritumomab tiuxetan (pronounced /ɪbrɪˈtuːmoʊmæb taɪˈʌksɛtæn/), sold under the trade name Zevalin, is a monoclonal antibody radioimmunotherapy treatment for non-Hodgkin's lymphoma. The drug uses the monoclonal mouse IgG1 antibody ibritumomab in conjunction with the chelator tiuxetan, to which a radioactive isotope (either yttrium-90 or indium-111) is added. Tiuxetan is a modified version of DTPA whose carbon backbone contains an isothiocyanatobenzyl and a methyl group.
Medical use
Ibritumomab tiuxetan is used to treat relapsed or refractory, low grade or transformed B cell non-Hodgkin's lymphoma (NHL), a lymphoproliferative disorder, and previously untreated follicular NHL in adults who achieve a partial or complete response to first-line chemotherapy.
The treatment starts with an infusion of rituximab. This may be followed by an administration of indium-111 labeled ibritumomab tiuxetan (In replaces the Y component) to allow the distribution of the medication to be imaged on a gamma camera, before the actual therapy is administered.
Mechanism of action
The antibody binds to the CD20 antigen found on the surface of normal and malignant B cells (but not B cell precursors), allowing radiation from the attached isotope (mostly beta emission) to kill it and some nearby cells. In addition, the antibody itself may trigger cell death via antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis. Together, these actions eliminate B cells from the body, allowing a new population of healthy B cells to develop from lymphoid stem cells.
History
Developed by IDEC Pharmaceuticals, now part of Biogen Idec, ibritumomab tiuxetan was the first radioimmunotherapy drug approved by the US Food and Drug Administration (FDA) in 2002 to treat cancer. It was approved for the treatment of people with relapsed or refractory, low‑grade or follicular B‑cell non‑Hodgkin's lymphoma (NHL), including people with rituximab refractory follicular NHL. It was given marketing authorization by the European Medicines Agency in 2004 for the treatment of adults with rituximab relapsed or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma but. The authorization lapsed in July 2024, after it wasn't marketed for more than three consecutive years.
In September 2009, ibritumomab tiuxetan received approval from the FDA for an expanded label to include previously untreated people with a chemotherapy response.
Society and culture
Economics
Ibritumomab tiuxetan is under patent protection and not available in generic form. When approved, it was the most expensive medication available given in a single dose, costing over US$37,000 (€30,000) for the average dose. Compared with other monoclonal antibody treatments (many of which are well over $40,000 for a course of therapy), it may be considered cost effective.
References
- ^ "Zevalin EPAR". European Medicines Agency. 2 March 2009. Retrieved 11 July 2024.
- "Ibritumomab Tiuxetan". National Cancer Institute. 26 February 2008. Retrieved 25 July 2020.
- Milenic DE, Brady ED, Brechbiel MW (June 2004). "Antibody-targeted radiation cancer therapy". Nature Reviews. Drug Discovery. 3 (6): 488–99. doi:10.1038/nrd1413. PMID 15173838. S2CID 22166498.
- WHO Drug Information
- ^ Schaefer NG, Huang P, Buchanan JW, Wahl RL (May 2011). "Radioimmunotherapy in non-Hodgkin lymphoma: opinions of nuclear medicine physicians and radiation oncologists". Journal of Nuclear Medicine. 52 (5): 830–8. doi:10.2967/jnumed.110.085589. PMC 4380183. PMID 21536931.
- Tennvall J, Fischer M, Bischof Delaloye A, Bombardieri E, Bodei L, Giammarile F, et al. (April 2007). "EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin)". European Journal of Nuclear Medicine and Molecular Imaging. 34 (4): 616–622. doi:10.1007/s00259-007-0372-y. PMID 17323056. S2CID 8951564.
{{cite journal}}: CS1 maint: overridden setting (link) - "Ibritumomab Tiuxetan" (PDF). US Food and Drug Administration.
- Pollack A (24 June 2003). "Idec to Merge With Biogen in $6.8 Billion Deal". The New York Times.
- Grillo-López AJ (October 2002). "Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma". Expert Review of Anticancer Therapy. 2 (5): 485–93. doi:10.1586/14737140.2.5.485. PMID 12382517. S2CID 20940701.
- ^ Cutler CS (September 2019). "Economics of New Molecular Targeted Personalized Radiopharmaceuticals". Seminars in Nuclear Medicine. 49 (5): 450–457. doi:10.1053/j.semnuclmed.2019.07.002. OSTI 1556887. PMID 31470937. S2CID 201758449.
- Bazell R (23 June 2004). "Why are the new cancer drugs so expensive?". Slate Magazine.
- Chen Q, Ayer T, Nastoupil LJ, Rose AC, Flowers CR (March 2015). "Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma". Value in Health. 18 (2): 189–197. doi:10.1016/j.jval.2014.12.017. PMC 4363091. PMID 25773554.
| Therapeutic radiopharmaceuticals (V10) | |||||
|---|---|---|---|---|---|
| Pain palliation | |||||
| Adrenergic tumors | |||||
| CD20 antibodies | |||||
| Radionuclides |
| ||||
Isotopes used:
| |||||
| Targeted cancer therapy / antineoplastic agents (L01) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CI monoclonal antibodies ("-mab") |
| ||||||||
| Tyrosine kinase inhibitors ("-nib") |
| ||||||||
| Other |
| ||||||||
